G Marchesini
Overview
Explore the profile of G Marchesini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
212
Citations
4646
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Marchesini G, Fossaluzza D, Palme R, Andrighetto I, Magrin L, Serva L
J Dairy Sci
. 2024 Feb;
107(7):4973-4986.
PMID: 38369120
Besides health monitoring, a regular check of dairy heifers' growth rate is desirable, but it is rarely done because procedures that require restraint and handling can be associated with substantial...
2.
Marchesini G, Gibertoni D, Giansante C, Perlangeli V, Grilli R, Scudeller L, et al.
J Endocrinol Invest
. 2023 Jul;
47(2):411-420.
PMID: 37474878
Purpose: To investigate the impact of diabetes in immigrants on the Italian healthcare system, as well as their compliance with standard protocols of control and treatment. Methods: The prevalence of...
3.
Morelli G, Marchesini G, Contiero B, Fusi E, Diez M, Ricci R
J Appl Anim Welf Sci
. 2019 Feb;
23(1):1-9.
PMID: 30773055
Commercially available dog treats have become very popular and a common part of the pet's diet, yet very little is known about peoples' opinions and feeding habits; therefore, a survey...
4.
Ermini G, Tosetti C, Zocchi D, Mandreoli M, Caletti M, Marchesini G
J Endocrinol Invest
. 2018 Nov;
42(7):787-796.
PMID: 30465248
Aims: Progressive chronic kidney disease represents a dreadful complication of type 2 diabetes mellitus (T2DM). We tested the pattern of use and the renal effects of old glucose-lowering drugs in...
5.
Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, et al.
Nutr Metab Cardiovasc Dis
. 2018 Apr;
28(6):533-542.
PMID: 29625780
Sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) have consistently demonstrated a clinically significant reduction of cardiovascular mortality. However, their safety in clinical practice is still incompletely characterized, and post-marketing monitoring is required considering...
6.
Raschi E, Parisotto M, Forcesi E, La Placa M, Marchesini G, De Ponti F, et al.
Nutr Metab Cardiovasc Dis
. 2017 Nov;
27(12):1098-1107.
PMID: 29174026
Background And Aims: We assessed post-marketing safety of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) by analyzing adverse events (AEs) reported in international pharmacovigilance databases. Methods And Results: Eudravigilance, WHO-Vigibase (as of Feb...
7.
Nuccitelli C, Valentini A, Caletti M, Caselli C, Mazzella N, Forlani G, et al.
J Endocrinol Invest
. 2017 Aug;
41(3):307-314.
PMID: 28803346
Background: Despite intensive training, a few individuals with Type 1 diabetes mellitus (T1DM) fail to reach the desired metabolic targets. Aim: To evaluate the association between disease-related emotional and cognitive...
8.
Petta S, Ciminnisi S, Di Marco V, Cabibi D, Camma C, Licata A, et al.
Aliment Pharmacol Ther
. 2016 Dec;
45(4):510-518.
PMID: 28028821
Background: Sarcopenia recognises insulin resistance and obesity as risk factors, and is frequently associated with cardiometabolic disorders, including non-alcoholic fatty liver disease (NAFLD). Aim: To test the prevalence of sarcopenia...
9.
Bruno G, Pagano E, Rossi E, Cataudella S, de Rosa M, Marchesini G, et al.
Nutr Metab Cardiovasc Dis
. 2016 Nov;
26(12):1104-1111.
PMID: 27817991
Background And Aims: To assess temporal trend in incidence (2003-12) and prevalence (2002-12) of type 1 diabetes in children and young adults, direct costs and selected indicators of quality of...
10.
Munteanu M, Tiniakos D, Anstee Q, Charlotte F, Marchesini G, Bugianesi E, et al.
Aliment Pharmacol Ther
. 2016 Aug;
44(8):877-89.
PMID: 27549244
Background: Blood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis. Aims: To improve the validation of three...